Special Episode: FDA Approves Tenecteplase for Acute Ischemic Stroke

Bijoy Menon, MD, MSc, FRCPC

A special episode of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

This special episode episode, "FDA Approves Tenecteplase for Acute Ishemic Stroke" features an exclusive interview with stroke expert Bijoy Menon, MD, MSc, FRCPC, discussing the FDA's recent approval of tenecteplase, marketed as TNKase (Genentech), for the treatment of acute ischemic stroke (AIS). Menon, a professor of neurology at the University of Calgary, discussed the significance of the new thrombolytic agent, how its administered, and its safety considerations clinicians should be aware of. In addition, he provided clinical insight on the trial that led to its approval, the phase 3 AcT study (NCT03889249), as well as supplemental evidence that supported the therapy's benefits. Furthermore, Menon gave commentary on how the approval works towards the idea of precision medicine and personalizing treatment choices for patients with AIS.

For more of NeurologyLive's coverage of tenecteplase's approval, head here: FDA Approves Tenecteplase for Acute Ischemic Stroke

EPISODE BREAKDOWN

• 1:40 – Immediate reaction and significance of tenecteplase approval
• 5:30 – Safety considerations and administration when prescribing tenecteplase
• 10:20 – Supportive efficacy and safety, phase 3 AcT trial, and other supplementary studies
• 14:50 – Advancing precision medicine, treatment personalization with new approval

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults. News release. Genentech. March 3, 2025. Accessed March 3, 2025. https://www.gene.com/media/press-releases/15053/2025-03-03/fda-approves-genentechs-tnkase-in-acute-